These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7428786)

  • 1. A comparison of the therapeutic effects of free and liposomally encapsulated vincristine in leukemic mice.
    Layton D; Trouet A
    Eur J Cancer (1965); 1980 Jul; 16(7):945-50. PubMed ID: 7428786
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
    Shinoda H; Inaba M; Tsuruo T
    Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance studies on intraspecific hybridomas.
    Pályi I; Turi G; Szikla K; Dallmann L
    Arch Geschwulstforsch; 1981; 51(1):119-24. PubMed ID: 7259434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
    Inaba M; Maruyama E
    Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of chemotherapeutic effect of vincristine in vincristine resistant tumor bearing mice by calmodulin inhibitor clomipramine.
    Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
    J Pharmacobiodyn; 1983 Feb; 6(2):145-7. PubMed ID: 6864439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Treat Rep; 1985 May; 69(5):523-5. PubMed ID: 4005874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
    Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
    Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cells.
    Nogae I; Kikuchi J; Yamaguchi T; Nakagawa M; Shiraishi N; Kuwano M
    Br J Cancer; 1987 Sep; 56(3):267-72. PubMed ID: 3663474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors.
    Boman NL; Masin D; Mayer LD; Cullis PR; Bally MB
    Cancer Res; 1994 Jun; 54(11):2830-3. PubMed ID: 8187061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of murine testicular leukemia.
    Hoots WK; Nelson JA
    Cancer Res; 1984 Jun; 44(6):2464-6. PubMed ID: 6722788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.
    Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y
    Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination vincristine and VP-16-213: evaluation of drug sequence.
    Jackson DV; Long TR; Rice DG; Morgan TM
    Cancer Biochem Biophys; 1986 Oct; 8(4):265-75. PubMed ID: 3802048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cis-diamminedichloroplatinum and vincristine.
    Adwankar MK; Khandalekar DD; Chitnis MP
    Oncology; 1984; 41(5):370-3. PubMed ID: 6540853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine.
    Inaba M; Fujikura R; Tsukagoshi S; Sakurai Y
    Biochem Pharmacol; 1981 Aug; 30(15):2191-4. PubMed ID: 7295334
    [No Abstract]   [Full Text] [Related]  

  • 15. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
    Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
    J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamic acid modification of vincristine toxicity.
    Jackson DV; Rosenbaum DL; Carlisle LJ; Long TR; Wells HB; Spurr CL
    Cancer Biochem Biophys; 1984 Sep; 7(3):245-52. PubMed ID: 6149015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice.
    Lin TS; Fischer PH; Prusoff WH
    Biochem Pharmacol; 1982 Jan; 31(1):125-8. PubMed ID: 7059345
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological evaluation of combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones.
    Li LH; Wallace TL; Hamilton RD; DeKoning TF
    Int J Immunopharmacol; 1987; 9(1):31-9. PubMed ID: 3583503
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia.
    Sava G; Giraldi T; Bartoli-Klugmann F; Decorti G; Mallardi F
    Eur J Cancer Clin Oncol; 1984 Feb; 20(2):287-9. PubMed ID: 6538492
    [No Abstract]   [Full Text] [Related]  

  • 20. Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.
    Ganu UK; Khandalekar DD; Gokhale SV
    Indian J Physiol Pharmacol; 1984; 28(1):21-6. PubMed ID: 6490126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.